Skip to content

Study · Non-randomized trial · 1987

10 results

Insulin and C-peptide secretory responses to glucagon in man: studies on the dose-response relationships.

Ahrén B, Nobin A, Scherstén B

Acta medica Scandinavica1 Jan 1987Cited by 15 (Europe PMC)

PMID3296670 (opens in a new tab)DOI10.1111/j.0954-6820.1987.tb01265.x (opens in a new tab)PepBankPUB-03296670
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanNon-randomized trialMechanism

    In non-diabetic humans, glucagon transiently increased plasma insulin concentrations.

    In plain wordsIn people without diabetes, glucagon briefly increased blood insulin levels.

    Peptide
    Glucagon
    Outcome
    IncreaseTransient plasma insulin increase
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · injectionAs given in this study (human).

    Source sentences

    Summary
    Glucagon induced a transient increase in plasma insulin and C-peptide concentrations.
    1 context sentence
    Summary · context
    The present study investigated the insulin and C-peptide secretory responses to glucagon in non-diabetic humans.
  2. 02HumanNon-randomized trialMechanism

    In non-diabetic humans, glucagon transiently increased plasma C-peptide concentrations.

    In plain wordsIn people without diabetes, glucagon briefly increased blood C-peptide levels.

    Peptide
    Glucagon
    Outcome
    IncreaseTransient plasma C-peptide increase
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · injectionAs given in this study (human).

    Source sentences

    Summary
    Glucagon induced a transient increase in plasma insulin and C-peptide concentrations.
    1 context sentence
    Summary · context
    The present study investigated the insulin and C-peptide secretory responses to glucagon in non-diabetic humans.
  3. 03HumanNon-randomized trialMechanism

    In non-diabetic humans, glucagon 0.5 mg elicited a greater insulin response than 0.25 mg (p less than 0.05).

    In plain wordsIn people without diabetes, glucagon 0.5 mg produced a greater insulin response than 0.25 mg.

    Peptide
    Glucagon
    Outcome
    IncreaseInsulin response at 0.5 versus 0.25 mg
    Study

    n: not reported in source

    Comparator
    Glucagon 0.25 mg
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    0.5 mg · injectionAs given in this study (human).

    Measurements

    p
    < 0.05
    0.5 versus 0.25 mg

    Source sentences

    Summary
    At the dose level of 0.5 mg, glucagon elicited more efficient responses than at the dose level of 0.25 mg (p less than 0.05).
    2 context sentences
    Summary · context
    The present study investigated the insulin and C-peptide secretory responses to glucagon in non-diabetic humans.
    Summary · context
    Glucagon induced a transient increase in plasma insulin and C-peptide concentrations.
  4. 04HumanNon-randomized trialMechanism

    In non-diabetic humans, glucagon 0.5 mg elicited a greater C-peptide response than 0.25 mg (p less than 0.05).

    In plain wordsIn people without diabetes, glucagon 0.5 mg produced a greater C-peptide response than 0.25 mg.

    Peptide
    Glucagon
    Outcome
    IncreaseC-peptide response at 0.5 versus 0.25 mg
    Study

    n: not reported in source

    Comparator
    Glucagon 0.25 mg
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    0.5 mg · injectionAs given in this study (human).

    Measurements

    p
    < 0.05
    0.5 versus 0.25 mg

    Source sentences

    Summary
    At the dose level of 0.5 mg, glucagon elicited more efficient responses than at the dose level of 0.25 mg (p less than 0.05).
    2 context sentences
    Summary · context
    Glucagon induced a transient increase in plasma insulin and C-peptide concentrations.
    Summary · context
    The present study investigated the insulin and C-peptide secretory responses to glucagon in non-diabetic humans.
  5. 05HumanNon-randomized trialMechanism

    In non-diabetic humans, glucagon 1.0 mg did not further potentiate the insulin response beyond 0.5 mg.

    In plain wordsIn people without diabetes, glucagon 1.0 mg did not further increase the insulin response beyond 0.5 mg.

    Peptide
    Glucagon
    Outcome
    No significant changeInsulin response at 1.0 versus 0.5 mg
    Study

    n: not reported in source

    Comparator
    Glucagon 0.5 mg
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    1.0 mg · injectionAs given in this study (human).

    Source sentences

    Summary
    However, the responses were not further potentiated by glucagon at 1.0 mg.
    3 context sentences
    Summary · context
    At the dose level of 0.5 mg, glucagon elicited more efficient responses than at the dose level of 0.25 mg (p less than 0.05).
    Summary · context
    Glucagon induced a transient increase in plasma insulin and C-peptide concentrations.
    Summary · context
    The present study investigated the insulin and C-peptide secretory responses to glucagon in non-diabetic humans.
  6. 06HumanNon-randomized trialMechanism

    In non-diabetic humans, glucagon 1.0 mg did not further potentiate the C-peptide response beyond 0.5 mg.

    In plain wordsIn people without diabetes, glucagon 1.0 mg did not further increase the C-peptide response beyond 0.5 mg.

    Peptide
    Glucagon
    Outcome
    No significant changeC-peptide response at 1.0 versus 0.5 mg
    Study

    n: not reported in source

    Comparator
    Glucagon 0.5 mg
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    1.0 mg · injectionAs given in this study (human).

    Source sentences

    Summary
    However, the responses were not further potentiated by glucagon at 1.0 mg.
    3 context sentences
    Summary · context
    At the dose level of 0.5 mg, glucagon elicited more efficient responses than at the dose level of 0.25 mg (p less than 0.05).
    Summary · context
    Glucagon induced a transient increase in plasma insulin and C-peptide concentrations.
    Summary · context
    The present study investigated the insulin and C-peptide secretory responses to glucagon in non-diabetic humans.
  7. 07HumanNon-randomized trialMechanism

    In non-diabetic humans, plasma glucose did not change during the first 2 min after glucagon injection.

    In plain wordsIn people without diabetes, blood glucose did not change during the first 2 minutes after glucagon injection.

    Peptide
    Glucagon
    Outcome
    No significant changePlasma glucose during first 2 minutes
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · injectionAs given in this study (human).

    Source sentences

    Summary
    Plasma glucose levels did not change during the first 2 min after glucagon injection, when already a marked increase in plasma insulin and C-peptide levels were observed.
    1 context sentence
    Summary · context
    The present study investigated the insulin and C-peptide secretory responses to glucagon in non-diabetic humans.
  8. 08HumanNon-randomized trialMechanism

    In non-diabetic humans, plasma glucose subsequently increased and peaked 20 min after glucagon injection.

    In plain wordsIn people without diabetes, blood glucose subsequently increased and peaked 20 minutes after glucagon injection.

    Peptide
    Glucagon
    Outcome
    IncreaseDelayed plasma glucose rise
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · injectionAs given in this study (human).

    Measurements

    Time to maximal glucose
    20 min
    after injection

    Source sentences

    Summary
    Thereafter, however, plasma glucose levels increased, to be maximal at 20 min after glucagon injection.
    1 context sentence
    Summary · context
    The present study investigated the insulin and C-peptide secretory responses to glucagon in non-diabetic humans.
  9. 09HumanNon-randomized trialMechanism

    In non-diabetic humans, insulin increments were 32 +/- 7% of C-peptide increments during the first 2 min after glucagon.

    In plain wordsIn people without diabetes, early insulin increases after glucagon were 32% of C-peptide increases.

    Peptide
    Glucagon
    Outcome
    Not applicableInsulin increment relative to C-peptide in first 2 minutes
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · injectionAs given in this study (human).

    Measurements

    Relative insulin increment
    32%
    first 2 min
    Reported variability
    7%
    first 2 min

    Source sentences

    Summary
    Calculations of the minute-to-minute increase of plasma insulin and C-peptide levels revealed that plasma insulin levels increased by 32 +/- 7% of the increase in plasma C-peptide levels during the first 2 min, and by 36 +/- 6% of the increase in plasma C-peptide levels during the 3rd and 4th min after injection;
    1 context sentence
    Summary · context
    The present study investigated the insulin and C-peptide secretory responses to glucagon in non-diabetic humans.
  10. 10HumanNon-randomized trialMechanism

    In non-diabetic humans, insulin increments were 36 +/- 6% of C-peptide increments during the 3rd and 4th min after glucagon.

    In plain wordsIn people without diabetes, insulin increases after glucagon were 36% of C-peptide increases during the third and fourth minutes.

    Peptide
    Glucagon
    Outcome
    Not applicableInsulin increment relative to C-peptide during minutes 3 and 4
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · injectionAs given in this study (human).

    Measurements

    Relative insulin increment
    36%
    3rd and 4th min
    Reported variability
    6%
    3rd and 4th min

    Source sentences

    Summary
    Calculations of the minute-to-minute increase of plasma insulin and C-peptide levels revealed that plasma insulin levels increased by 32 +/- 7% of the increase in plasma C-peptide levels during the first 2 min, and by 36 +/- 6% of the increase in plasma C-peptide levels during the 3rd and 4th min after injection;
    1 context sentence
    Summary · context
    The present study investigated the insulin and C-peptide secretory responses to glucagon in non-diabetic humans.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.